BNP Paribas Asset Management
VRDN icon

BNP Paribas Asset Management’s Viridian Therapeutics VRDN Stock Holding History

BNP Paribas Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.47M Sell
134,455
-5,805
-4% -$93.5K ﹤0.01% 1072
2026
Q1 		$2.74M Buy
140,260
+139,364
+15,554% +$4.14M ﹤0.01% 1004
2025
Q4 		$28K Buy
896
+327
+57% +$8.97K ﹤0.01% 1845
2025
Q3 		$12K Sell
569
-111
-16% -$2K ﹤0.01% 1585
2025
Q2 		$10K Buy
+680
New +$9.23K ﹤0.01% 1792

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BNP Paribas Asset Management's VRDN Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Viridian Therapeutics (VRDN) stake by 4.1% in Q2 2026, selling an estimated $93.5K and leaving 134,455 shares worth $2.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1072.

BNP Paribas Asset Management first reported a position in VRDN in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.74M in Q1 2026. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • BNP Paribas Asset Management held 134,455 shares of Viridian Therapeutics worth $2.47M as of Q2 2026.
  • BNP Paribas Asset Management sold 5,805 Viridian Therapeutics shares in Q2 2026, an estimated $93.5K.
  • Viridian Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1072 holding.
  • BNP Paribas Asset Management first reported a position in Viridian Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Asset Management's Viridian Therapeutics position peaked at $2.74M in Q1 2026.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.